Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Salvage Therapy. Found 20 abstracts

Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017 Nov 15;123(22):4411-8.
Gore JL, du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson DJ, Karsh L, Lane BR, Franks M, Chen DY, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Davicioni E, Lotan Y, Lin DW. Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study. Cancer. 2017 Aug;123(15):2850-9.   PMCID: PMC5573983
Xu MJ, Chu C, Rubin S, Lin LL. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. Am J Clin Oncol. 2017 Dec;40(6):598-604.   PMCID: PMC4733581
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb;13(1):71-9.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr;13(2):185-92.
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol. 2008 Sep;3(9):1032-8.
National Comprehensive Cancer Network, Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A, Weber RS, Wolf GT, Worden F. Head and neck cancers. J Natl Compr Canc Netw. 2008 Aug;6(7):646-95.
Engstrom PF, Benson AB, Chen YJ, Choti MA, Dilawari RA, Enke CA, Fakih MG, Fuchs C, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW, Rao S, Saif MW, Saltz L, Skibber JM, Venook AP, Yeatman TJ, National Comprehensive Cancer N. Colon cancer clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2005 Jul;3(4):468-91.
Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Jul;56(3):755-63.
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
Langer CJ. Does salvage therapy influence outcome?. J Clin Oncol. 2001 Apr;19(7):2108-9.
Chao C, Goldberg M, Hoffman JP. Surgical salvage therapy: abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation. Curr Opin Oncol. 2000 Jul;12(4):353-6.
Freedman GM, Fowble BL. Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Huntingt). 2000 Nov;14(11):1561-81; discussion 1581-2, 1582-4.
Langer CJ. Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Invest New Drugs. 2000 Feb;18(1):17-28.
Ozols RF. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Watson JC, Ridge JA. Surgical management of local and regional recurrent head and neck squamous cell carcinoma. Curr Opin Oncol. 1998 May;10(3):207-12.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Salvage Therapy

Salvage Therapy drug therapy therapeutic use pathology Female Human Antineoplastic Combined Chemotherapy Protocols mortality therapy Aged Middle Aged Male Local Neoplasm Recurrence Adult administration & dosage methods Neoplasm Staging Adjuvant Radiotherapy radiotherapy Treatment Outcome Head and Neck Neoplasms Squamous Cell Carcinoma Antineoplastic Agents surgery Paclitaxel Survival Analysis Survival Rate Prospective Studies analogs & derivatives Recurrence Combined Modality Therapy Retrospective Studies Phase II Clinical Trials as Topic Prognosis Neoplasm Drug Resistance Non-Small-Cell Lung Carcinoma Lung Neoplasms Disease-Free Survival Randomized Controlled Trials Liver Neoplasms Rectal Neoplasms Clinical Trials Chemoradiotherapy Deoxycytidine epidemiology drug effects Lymph Node Excision Risk Factors Urologic Neoplasms diagnosis Incidence Drug Administration Schedule Carboplatin Radiation-Sensitizing Agents Adjuvant Chemotherapy Non-US Gov't Support Lymphatic Metastasis Neoplasm Metastasis Ovarian Neoplasms Prostatectomy 80 and over Aged Risk Assessment Prostatic Neoplasms Taxoids Endometrioid Carcinoma su [Surgery] Middle Age blood Camptothecin Multivariate Analysis prostate cancer Remission Induction Leucovorin Transitional Cell Carcinoma Complete response Breast Neoplasms non-Hodgkin lymphoma Salvage therapy Prior perioperative chemotherapy Half-Life Capecitabine Proportional Hazards Models Hematopoietic Stem Cell Transplantation Peripheral Nervous System Diseases Young Adult Urothelium Palliative Care etiology Laryngeal Neoplasms genetics biosynthesis adverse myc Genes Radiotherapy Dosage Epidermal Growth Factor Receptor Perineum Colonic Neoplasms Neoplastic Gene Expression Regulation US Gov't Support-PHS Radiotherapy adjuvant therapy Population Surveillance Drug Therapy Urinary Bladder Neoplasms Hysterectomy Antineoplastic Antibiotics effects hematopoietic cell transplantation (HCT) Perioperative Care US Gov't Support-Non-PHS Phytogenic Antineoplastic Agents Fluorouracil United States Mouth Neoplasms diffuse large B-cell lymphoma (DLBCL) Advanced urothelial carcinoma Abdominal Neoplasms di [Diagnosis] 0 (Antineoplastic Combined Chemotherapy Protocols) Abdomen chemically induced Hematologic Diseases th [Therapy] Phase III Clinical Trials Epidemiologic Methods Patient Selection pharmacology Large B-Cell Lymphoma-Diffuse pharmacokinetics Neoplasm Invasiveness Epothilones salvage therapy secondary Prostate-Specific Antigen Genetic Translocation Interdisciplinary Communication MYC proto-oncogene Endometrial Neoplasms st [Standards] Medical Oncology Nasopharyngeal Neoplasms Neoplasm Grading Logistic Models Pelvic Neoplasms sc [Secondary] Neck Dissection Decision Making Cystic Neoplasms-Mucinous-and Serous prostatectomy Time Factors
Last updated on Saturday, July 04, 2020